Surgery Partners (NASDAQ:SGRY) Insider Sells $105,209.60 in Stock

Key Points

• Danielle Burkhalter sold 7,736 shares at $13.60 for a total of $105,209.60, trimming her stake by 17.25% to 37,103 shares (≈$504,600).
• Surgery Partners missed Q4 EPS expectations (reported $0.12 vs. $0.31 consensus) but posted $885M revenue, and its board authorized a $200M stock buyback (up to 9.7% of shares).
• Several executives (including the CEO and CFO) also sold shares the week of Mar 5–6 and a shareholder fraud probe is underway, raising legal/uncertainty risks despite a MarketBeat consensus of “Moderate Buy” and trimmed analyst price targets.

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) insider Danielle Burkhalter sold 7,736 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $13.60, for a total value of $105,209.60. Following the sale, the insider owned 37,103 shares in the company, valued at approximately $504,600.80. This represents a 17.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Surgery Partners Stock Down 0.4%

Shares of SGRY stock traded down $0.06 during mid-day trading on Monday, hitting $13.30. The company's stock had a trading volume of 1,453,571 shares, compared to its average volume of 1,733,344. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -21.45 and a beta of 1.95. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. Surgery Partners, Inc. has a 52-week low of $12.25 and a 52-week high of $24.60. The business has a 50-day moving average price of $15.16 and a 200 day moving average price of $18.00.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The business had revenue of $885.00 million during the quarter, compared to the consensus estimate of $866.54 million. During the same quarter in the previous year, the business posted $0.44 earnings per share. Surgery Partners's quarterly revenue was up 2.4% compared to the same quarter last year. Research analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners declared that its board has authorized a stock repurchase plan on Thursday, February 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to repurchase up to 9.7% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SGRY. Jefferies Financial Group reiterated a "buy" rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Mizuho lowered their target price on Surgery Partners from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Thursday. TD Cowen cut their price target on Surgery Partners from $28.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday. JPMorgan Chase & Co. reduced their price target on shares of Surgery Partners from $27.00 to $20.00 and set a "neutral" rating for the company in a research report on Monday, November 24th. Finally, Royal Bank Of Canada dropped their price objective on shares of Surgery Partners from $31.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday, March 4th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Surgery Partners has a consensus rating of "Moderate Buy" and an average price target of $24.45.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Groupe la Francaise increased its holdings in Surgery Partners by 26.6% in the 2nd quarter. Groupe la Francaise now owns 186,088 shares of the company's stock worth $4,137,000 after acquiring an additional 39,089 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. boosted its position in shares of Surgery Partners by 87.9% in the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 146,250 shares of the company's stock worth $3,251,000 after purchasing an additional 68,400 shares during the period. AYAL Capital Advisors Ltd purchased a new stake in shares of Surgery Partners in the second quarter worth $2,779,000. Norges Bank bought a new stake in shares of Surgery Partners during the 2nd quarter valued at $26,609,000. Finally, Vanguard Group Inc. lifted its stake in shares of Surgery Partners by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 7,614,514 shares of the company's stock valued at $164,778,000 after buying an additional 424,518 shares in the last quarter.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.